A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was, what is the optimal dose of aspirin post cardiac surgery that should be given to prevent graft occlusion and prolong survival. Altogether, 114 papers were found from Medline and 59 papers were found from the Cochrane Central Register of Controlled Trials using the reported search, of which seven presented the best evidence to answer the clinical question. The author, journal, date and country of publication, patient group studied, study type, relevant outcomes, results, and study weaknesses of these papers are tabulated. We conclude that best evidence suggests that 325 mg optimally improves vein graft survival and mortality, and does not cause an increase in complications compared to lower doses. q
Three-part question

In [patients following coronary arterial bypass graft]
what is the optimal dose of [aspirin] required to [prolonging event free survival]
Clinical scenario
You are ready to discharge a 57-year-old gentleman who has undergone CABG 8 days ago. It is your consultant's policy to discharge all people without contraindications on low dose aspirin, but you have recently attended a structured critical appraisal journal club and wonder whether a higher dose of aspirin may confer a survival advantage to your patient. 
Search strategy
Search outcome
One hundred and fourteen abstracts were found from medline and 59 papers from the Cochrane Central Register of Controlled Trials. Two meta-analyses were found from 1993/1994, which included all relevant studies pre-1991. Of the remaining papers, 104 were either irrelevant or of insufficient quality for inclusion and four further papers were relevant. The four papers and the two meta-analyses are shown in the table. The Journal Club also suggested one additional recent paper that had not yet been indexed by Medline, which is also included in the table [1 -7] . The papers are presented in Table 1 .
Comment(s)
Fremes' meta-analysis demonstrated a significant benefit of low and medium dose aspirin in comparison to high dose There are no studies that compare 50-100 mg/day to 325 mg/day but there is also no evidence to support the concept of reduced GI bleeding with low dose aspirin.
Aspirin does not increase IMA patency. Aspirin should be given lifelong to all patients with a diagnosis of coronary arterial disease. Grade 1A
Other meta-analyses were not considered.
The recommendation for lifelong aspirin in post CABG patients is based on mortality studies on patients with non-operated coronary arterial disease, which is a clearly different cohort to post-CABG patients.
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aspirin. The benefit of medium dose aspirin was greatest but confidence intervals cross the confidence intervals for low dose aspirin. Neither the anti-platelet trialists or the veterans study group were able to convincingly demonstrate an advantage of medium dose aspirin in comparison to low dose aspirin. Mangano et al. provide the first evidence for a convincing mortality benefit from aspirin. However, the range of aspirin used was from 80 to 650 mg, so no evidence was provided for choosing a dose within this range. Of note they also found a higher rate of GI and bleeding complications in the non-aspirin group. These findings have all been supported by the ACCP Consensus Conference on Antithrombotic Therapy. They recommend 325 mg/day as the current best evidence recommendation for aspirin post cardiac surgery.
Clinical bottom line
Best evidence suggests that 325 mg optimally improves vein graft survival and mortality, and does not cause an increase in complications compared to lower doses. 
